BuruliVac is funded by the EC under the 7th Framework Programme of the European Union

Welcome to BuruliVac

BuruliVac is a three-year Collaborative Project funded by the EC under the 7th Framework Programme of the European Union.

The overall objective of BuruliVac is to identify and develop novel vaccine candidates suitable for translation into clinical application. Information on disease immunopathology and immunological correlates of a protective capacity will be gained and will help to develop vaccine candidates that can be directly used in future clinical trials.

BuruliVac uses recent scientific advances in bioinformatics, applied genomics and proteomics. Research activities will be performed by a consortium combining complementary expertise, broad experience and the ability to exploit longstanding North-South interactions between beneficiaries. Active participation of industry is an integral part of BuruliVac and will lead to an enhanced impact in exploitation and dissemination.

The project addresses particular health conditions and health needs of disease endemic countries, in particular of their most vulnerable population and provides extensive technology transfer, training activities and human capacity building.

Thus, BuruliVac is a perfect example of cooperation between scientific disciplines and stakeholders at European level with disease-endemic countries on the basis of mutual interest and shared benefit.